-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
RSV604 R enantiomer
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/932108-20-8.gif)
| Category | Respiratory syncytial Virus (RSV) |
| CAS | 932108-20-8 |
| Description | RSV604 R enantiomer is the R-enantiomer of RSV604, an inhibitor of respiratory syncytial virus (RSV) replication. R-enantiomer is less active against RSV compared to RSV604. |
Product Information
| Synonyms | RSV604 (R enantiomer); RSV604 R enantiomer; 932108-20-8; 1-(2-fluorophenyl)-3-[(3R)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]urea; CHEMBL223191; HY-12993B; AKOS032944903; CS-6122; NCGC00522593-01 |
| IUPAC Name | 1-(2-fluorophenyl)-3-[(3R)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]urea |
| Molecular Weight | 388.39 |
| Molecular Formula | C22H17FN4O2 |
| Canonical SMILES | C1=CC=C(C=C1)C2=NC(C(=O)NC3=CC=CC=C32)NC(=O)NC4=CC=CC=C4F |
| InChI | InChI=1S/C22H17FN4O2/c23-16-11-5-7-13-18(16)25-22(29)27-20-21(28)24-17-12-6-4-10-15(17)19(26-20)14-8-2-1-3-9-14/h1-13,20H,(H,24,28)(H2,25,27,29)/t20-/m0/s1 |
| InChIKey | MTPVBMVUENFFLL-FQEVSTJZSA-N |
| Purity | ≥98% (HPLC) |
| Solubility | In Vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Target | RSV |
